ESMO 2023 | Evaluating the interchangeability of HRD testing in ovarian cancer

Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, comments on whether the various tests for homologous recombination deficiency (HRD) are comparable in ovarian cancer. HRD testing is necessary to optimize treatment, but each test will have different validation assays. Whilst these genomic tests have been validated with findings from the PAOLA-1 trial (NCT02477644), additional prospective data is required to conclusively determine the efficacy of these tests. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.